Latest news

International Society of Oncology Pharmacy Practitioners (ISOPP)

Updated 18 November

ISOPP is offering educational opportunities specific to the needs of oncology pharmacy practitioners worldwide. There are two complimentary opportunities for ISOPP members to share and expand knowledge, facilitated by ISOPP leaders and oncology pharmacy experts, are ISOPP 2022 Virtual Symposium and the OPAB Program.

Cancer Symptom Trials (CST)

Updated 11 November

The University of Otago Department of Medicine and Nurse Maude Hospice are working in collaboration as the ASPERT Research Group to address the perceived lack of access of Pancreatic Enzyme Replacement Therapy (PERT) by people with pancreatic cancer in Aotearoa New Zealand and Australia. We want to understand the prescribing of and compliance with PERT by investigating current practices in both countries with a view to highlighting the current gaps. If you are caring for someone in Australia or Aotearoa New Zealand who is diagnosed with pancreatic cancer, we invite you to click here to share our survey with them.

An exciting collaboration for NZSO, the ASCO Breakthrough Conference, 25-27th August in Yokohama, Japan

Updated 11 November

Join global leaders in oncology medicine, research, and technology to explore cutting edge science and a unique application of technology that is transforming cancer care with remarkable new therapies.

NZSO asco logo

NZFBOC - Invitation to register

Updated 19 October

The New Zealand Familial Breast and Ovarian Cancer Group (NZFBOC) was established in 2019. It connects people from specialist fields involved in a patient’s path of discovery, prevention, and treatment of familial breast and ovarian cancer.

Click here to register

Action Plan for improving diagnosis and treatment of lung cancer

Updated 4 October

Te Aho o Te Kahu, the Cancer Control Agency is committed to developing quality improvement processes that identify variations in care or cancer outcomes and supporting DHBs to develop quality improvement plans that address concerns identified.

NZSO te aho

Pancreatic Cancer Potential Quality Performance Indicator Descriptions Report consultation has extended to 15 October

Updated 4 October

With COVID-19 once again impacting life in Aotearoa I would like to thank each of you, and the wider sector, for your unwavering focus on caring for whānau living with cancer.

The Prostate Cancer Quality Improvement Monitoring Report is now available on the Te Aho o Te Kahu website

Updated 4 October

As you will be aware, there are around 4,000 new cases of prostate cancer each year and 695 deaths. Prostate cancer has a higher impact on Māori than other ethnicities with significant economic costs for treatment services and care.

Breast Cancer Foundation NZ’s 2022 Fellowship funding round is now open for applications

Updated 4 October

We are offering one clinical fellowship and one science fellowship, valued at up to $120,000 each, depending on the caliber of the applicant and the scope and costs of the proposed project.

Duration of the fellowship is 1-2 years, and it can be full-time or part-time. We are happy to discuss flexibility of timing and other conditions. Fellowships can be on any breast cancer-related subject, but here are some areas that interest us:

NZSO BCFNZ

Australasian Gastro-Intestinal Trials Group 23rd Annual Scientific Meeting

Updated 7th September

12-15 October 2021 | Virtual Conference
Convenor: Professor Stephen Ackland
https://asm.gicancer.org.au/

The AGITG Annual Scientific Meeting serves not only as a forum for the presentation of state-of-the art overviews on the pathobiological and clinical aspects of GI cancer, but also affords the opportunity to the Australasian scientific community to explore future directions for research and collaboration. The meeting provides GI cancer researchers and specialists with the opportunity to present their research and discuss the current challenges and recent innovations in a multidisciplinary setting.

click here to download PDF

NZSO Clinical Trials survey

Breast Cancer Research Review - Issue 34

Updated 6th September

Welcome to the latest issue of Breast Cancer Research Review.

We begin this issue with research from Germany that has successfully managed to enrol a reasonable number of men with hormone receptor-positive breast cancer to evaluate the impact of standard endocrine therapies on oestradiol levels.

PDF available to view here

Initiative to support vaccination

Updated 6th September

Kia ora koutou,

I am writing to you from Doctors Stand Up For Vaccination - which is a grassroots initiative by doctors, for doctors, to create an open letter to the people of Aotearoa New Zealand to stand together to support vaccination against COVID-19. You may have heard of our initiative already. We have the formal endorsement of ASMS, NZMA, RACP, ACEM, RANZCOG, NZCUC, and RNZCGPs. We do expect more endorsements over the next week.

Major new projects funded by Cancer Research Trust

Updated 19th August

Cancer Research Trust NZ has just awarded funding to three major new cancer research projects in Aotearoa New Zealand.

The three projects funded each target different kinds of cancer and use unique approaches. The University of Otago’s Associate Professor Brian Cox will be working to unravel some of the causes of head and neck cancer so that in future we can do more to prevent these cancers from occurring. At Auckland DHB, Dr Michelle Wilson’s research will mean New Zealand women with endometrial cancer can get involved in a groundbreaking trans-Tasman clinical trial to see whether adding immunotherapy to the current treatment offers a better quality of life and reduces the chance of the cancer recurring. Canterbury DHB’s Dr Tristan Pettit is investigating rhabdomyosarcoma – a rare cancer that is most often diagnosed in children. Dr Pettit will lead the New Zealand arm of FaR-RMS, an international clinical trial focused on improving survival and quality of life for newly diagnosed and relapsed rhabdomyosarcoma patients.

Cancer Research Trust - Help us raise money to fund more research!

Updated 19th August

You can help us to make our special call for public health and clinical trials an annual feature of funding calendar. We're on the lookout for new donors and supporters, and every dollar counts.

There are lots of ways you can get involved. Perhaps you're able to make a donation today, either a one-off amount or a regular weekly or monthly amount. No donation is too small, and as Cancer Research Trust NZ is a registered charity you'll receive a tax receipt for any donation over $5.

We have our own Givealittle page where you can donate, as well as many supporters who set up their own Givealittle pages to fundraise for us.

ESMO Important dates

Uploaded 26th July

  • ESMO Virtual Preceptorship on Head and Neck Cancer, 24-25 September 2021 - Online Application deadline: 4 August 2021

https://www.esmo.org/meetings/esmo-virtual-preceptorship-on-head-and-neck-cancer-2021

  • ESMO Virtual Preceptorship on Gastric Cancer, 17-18 November 2021 - Online Application deadline: 22 September 2021

https://www.esmo.org/meetings/esmo-virtual-preceptorship-on-gastric-cancer-2021-november

NZSO ESMO regular image 1

Precision Oncology Issue

Uploaded 26th July

Roche has commissioned Dr Angela George (Clinical Director of Genomics at the Royal Marsden Hospital in London) to be the consulting editor on this newsletter, Perspectives of Precision Oncology. This is issue 1 of 5 to be released in 2021, and will include follow on from ASCO meeting, as well as NZSO’s meeting.

Lymphoma and Leukaemia Research Review

Uploaded 20th July 2021

The Release of the Position Statement: Role of the oncology pharmacy team in cancer care

Uploaded 20th July 2021

Vancouver, BC (July 8, 2021) – The International Society of Oncology Pharmacy Practitioners (ISOPP) is pleased to announce the publication of its “Position Statement: Role of the oncology pharmacy team in cancer care” in the Journal of Oncology Pharmacy Practice (JOPP).

The Position Statement describes the roles of oncology pharmacists and technicians in cancer patient care and provides information that promotes advocacy, especially for countries where the profession has not yet recognized oncology pharmacy as a specialty.

ASCO Leadership Development Program Asia Pacific

The ASCO Leadership Development Program for the Asia-Pacific region (LDP-AP) teaches culturally-relevant skills in leadership, advocacy, communication, presentation skills, media skills, and conflict management. Participants will be selected based on their commitment to improving cancer care and potential for leadership. At the conclusion of the program, participants will be better able to lead successful advocacy efforts, to build relationships with leaders within their countries, and to lead within their own societies, institutions, and ASCO.


Notice of discontinuation of CeeNU Australia and New Zealand

Bristol Myers Squibb would like to inform you that the sale and distribution of CeeNU (lomustine) will be discontinued in Australia and New Zealand in December 2022. This discontinuation includes all dose strengths (10mg and 40mg). The decision to discontinue CeeNU is due to declining demand and the availability of newer, preferred therapies (recommended by current treatment guidelines) for the treatment of brain tumours, such as glioblastomas. As such, the decision to discontinue CeeNU is voluntary and not related to any quality, safety or efficacy issues regarding the product.

NZSO Bristol meyers squibb

Welcome to the sixth issue of Skin Cancer Research Review.

This issue includes research reporting that patients who relapse after adjuvant targeted therapy for BRAFmutated stage III melanoma respond well to subsequent anti-PD-1-based therapy with outcomes similar to those seen with first-line anti-PD-1 therapy for stage IV melanoma. We have also included a long-term safety report from three of the KEYNOTE trials of pembrolizumab monotherapy for melanoma. Research conducted in participants from a dermoscopy masterclass found that the accuracy of diagnosing lentigo maligna improved after they were trained in the inverse approach, added to the classic pattern analysis. This issue concludes with an Australian study investigating discrepancies between biopsy results and final excised specimens in keratinocyte carcinomas.

We hope you enjoy the research selected, and we look forward to your comments and feedback.

Kind regards,
Dr Annie Wong

Are you a doctor, nurse or allied healthcare professional working in Aotearoa?

We invite Maori and non-Maori healthcare professionals who have provided care for patients with cancer to take part in a brief online survey. iPad Mini up for grabs.

Click here to start the survey.

The call for nominations for medals and awards for the 2021 round is now open.

Please note that the Academy Executive Committee is focused on increasing the diversity of nominations from under-represented groups, particularly with respect to gender, ethnicity and employment context, from Crown Research Institutes and Independent Research organisations.

Podcast episode featuring Diana Safartis

Please see below the podcast episode featuring a really in-depth interview with Diana Safarti, discussing Global Disparity of Cancer Care and specifically in the Pacific. Here’s the link for you to listen: https://oncologynews.com.au/th...

To subscribe to Oncology News Australia, which includes a mix of conference coverage, reviews, news, opinion pieces, podcasts –https://us7.list-manage.com/su...

NZSO THE ONCOLOGY JOURNAL
NZSO Openness Agreement

Openness Agreement on the use of animals in research and teaching in New Zealand

Foreword from Professor Juliet Gerrard, The Prime Minister’s Chief Science Advisor:

Why the Openness Agreement was developed?

The Australia New Zealand Council for the Care of Animals in Research and Teaching (ANZCCART) is an independent body that was established to provide a focus for consideration of the scientific, ethical and social issues associated with the use of animals in research and teaching. After years of promoting openness in animal research, ANZCCART has taken the lead in developing this Agreement

Important research featured on Newshub

from our very own Executive Member, Associate Professor Logan Walker

Click here to see the importance of mandatory genetic screenings for women diagnosed with breast cancer.

NZSO Loganwalker news